Cognitive effects of hormone therapy in men with prostate cancer: A review Journal Article


Authors: Nelson, C. J.; Lee, J. S.; Gamboa, M. C.; Roth, A. J.
Article Title: Cognitive effects of hormone therapy in men with prostate cancer: A review
Abstract: BACKGROUND. Men who receive androgen-deprivation therapy (ADT) for prostate cancer experience several side effects from this treatment. A few recent studies have examined the cognitive implications of ADT and how they impact a patient's treatment decision-making, occupational pursuits, and quality of life. For this report, the authors explored possible mechanisms for this association, reviewed research in animal studies and aging men, and examined the growing literature focused on the relation between ADT and cognitive functioning in patients with prostate cancer. METHODS. A systematic literature search was conducted using the PubMed and Information Sciences Institute Web of Knowledge-Web of Science databases to identify relevant studies that investigated the relation between ADT in men with prostate cancer and its cognitive effects. RESULTS. Testosterone and its derivatives may have an impact on cognition through several mechanisms in the brain, as supported by studies of animals and in aging men. Studies that researched the impact of ADT on cognition in patients with prostate cancer patients were designed relatively well but suffered from small sample sizes. Between 47% and 69% of men on ADT declined in at least 1 cognitive area, most commonly in visuospatial abilities and executive functioning. Some studies reported contradictory results with increased functioning in verbal memory. CONCLUSIONS. There is a strong argument that androgen-ablation therapy is linked to subtle but significant cognitive declines in men with prostate cancer. The authors believe that clinicians should become aware of this correlation as the use of ADT increases and should inform and monitor patients for this possible side effect of treatment. © 2008 American Cancer Society.
Keywords: androgen; review; nonhuman; neoplasm; animal; animals; quality of life; patient monitoring; drug effect; data base; prostate cancer; prostatic neoplasms; goserelin; leuprorelin; blood; correlation analysis; drug mechanism; brain; medical research; prostate tumor; androgen ablation; androgen antagonists; cognition; physician; medline; medical literature; aging; therapy effect; hormonal therapy; antiandrogen; cyproterone acetate; antineoplastic agents, hormonal; verbal memory; hormone; awareness; estradiol; information science; testosterone; brain function; antineoplastic hormone agonists and antagonists; drug use; androstanolone; sample size; neoplasms, hormone-dependent; dihydrotestosterone; altered cognitive function; depth perception
Journal Title: Cancer
Volume: 113
Issue: 5
ISSN: 0008-543X
Publisher: Wiley Blackwell  
Date Published: 2008-09-01
Start Page: 1097
End Page: 1106
Language: English
DOI: 10.1002/cncr.23658
PUBMED: 18666210
PROVIDER: scopus
PMCID: PMC4333639
DOI/URL:
Notes: --- - "Cited By (since 1996): 27" - "Export Date: 17 November 2011" - "CODEN: CANCA" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Andrew J Roth
    104 Roth
  2. Christian Nelson
    391 Nelson
  3. Maria Cristina Gamboa
    1 Gamboa